Byvasda
-
October 8, 2020
Innovent Biologics’s TYVYT/Byvasda combo shows survival benefit in late-stage liver cancer study Bookmark
George Lundberg, MDArticle from Seeking Alpha curated by Contributing Editor George Lundberg, MD, who notes:
In a phase 3 clinical trial, a new drug combination improved both overall survival and progression-free survival for people with hepatocellular carcinoma.
.